Introduction
Class IA phosphatidylinositol-3-kinase (PI3K) activity is composed of catalytic subunits (p110a, p110b, or p110d) and regulatory subunits (p85a, p55a, p50a, or p85b) and is commonly upregulated in human malignancies as a result of somatic mutations in the genes encoding p110a and p85a. 1, 2 Although mutations in the gene encoding p110d have not been found, the p110d protein is commonly overexpressed in myeloid leukemia 3, 4 and is unique among the class IA catalytic subunits in its capacity to induce malignant transformation independent of Ras. 5 Juvenile myelomonocytic leukemia (JMML) is an aggressive childhood myeloproliferative neoplasm characterized as being Ras-driven because of mutations in NF1, CBL, KRAS, NRAS, or PTPN11. 6 Accordingly, inhibition of the Ras-Erk signaling pathway using mitogen-activated or extracellular signal-regulated protein kinase kinase (MEK) inhibitors effectively normalizes loss-of-function (LOF) Nf1-induced and gain-of-function (GOF) Kras-induced disease in murine models. 7, 8 These findings are relevant, as MEK inhibitors have demonstrated success in BRAF and NRAS mutant melanoma in humans. 9, 10 However, MEK inhibition is accompanied by undesirable and dose-limiting adverse effects. 9, 11, 12 Furthermore, resistance to MEK inhibitors commonly develops via multiple resistance mechanisms, including aberrant upregulation of the PI3K-Akt pathway. 13 Previous studies demonstrate that PTEN expression, a negative regulator of PI3K-Akt signaling, frequently is reduced in primary JMML samples.
14 Likewise, we recently found that genetic disruption of the PI3K regulatory subunit, p85a, normalizes GOF PTPN11-induced hypersensitivity to granulocyte macrophagecolony-stimulating factor (GM-CSF). 15 Thus, we hypothesized that PI3K hyperactivation promotes myeloid cell growth in JMML beyond the customary task of a hyperactivated Ras effector and that the PI3K catalytic subunit, p110d, uniquely promotes JMML because of its Ras-independent oncogenic properties.
Methods

Animal husbandry
Mice bearing a conditional GOF Ptpn11 allele (LSL-Shp2 D61Y/1 ) have been described. 16 There is an Inside Blood commentary on this article in this issue.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. Cre1. For colony-forming unit-GM and [
3 H]-thymidine incorporation assays, data were analyzed using mixed-effects models with random intercept, using GM-CSF concentration as a categorical variable. (F) Immunoblot demonstrating Erk and Akt hyperphosphorylation in D61Y;Cre1 mice compared with D61Y;Cre2 mice, without normalization on successful knockout of p110a protein expression in 2 independent D61Y;Cre1;p110a
Fl/Fl mice.
(G) Immunoblot demonstrating normalization of Erk and
Akt hyperphosphorylation in 2 independent D61Y;Cre1;p110d D910A/D910A mice compared with 2 independent D61Y;Cre1 mice. (H) Representative flow cytometry analysis demonstrating increased megakaryocyte erythroid progenitor and decreased granulocyte macrophage progenitor in D61Y;Cre1 mice compared with D61Y;Cre2 mice, as described previously. 16 (I) Quantification of phenotypically defined bone marrow myeloid precursor distribution. *P 5 .02, with the D61Y;Cre1;p110d D910A/D910A group being significantly closer to D61Y;Cre2 than the D61Y;Cre1;p110a Fl/Fl group to D61Y;Cre2. Progenitor distribution between genotypes was analyzed by comparing Euclidian distance between mean vectors to quantify the similarity among group mean levels, with the P value determined using the bootstrapping resampling method. ;Mx1Cre1 (D61Y;Cre1) mice in response to GM-CSF 1 ng/mL in the presence of increasing concentrations of the p110d-specific inhibitor, GS-9820; n 5 4. *P , .05 for D61Y;Cre1 cells treated with GS-9820 compared with no drug; statistics performed using unpaired, 2-tailed student's t test. ;Mx1Cre1 (D61Y;Cre1) mice in response to GM-CSF 1 ng/mL in the presence of the MEK inhibitor, PD-0325901, and increasing concentrations of the p110d-specific inhibitor, GS-9820; n 5 4. *P 5 .0002 for D61Y; Cre1 cells treated with 0.05 mM PD0325901 vs no PD0325901. **P 5 .01 or **P 5 .0002 for D61Y;Cre1 cells treated with either 0.05 mM PD0325901 1 0.1 mM GS-9820 or 0.05 mM PD0325901 1 1 mM GS-9820, respectively, compared with 0.05 mM PD-0325901, statistics performed using unpaired, 2-tailed student's t test. (D) Immunoblot demonstrating maximal inhibition of Erk and Akt activation in the presence of both PD0325901 and GS-9820. (E) Control human bone marrow LDMNCs or primary JMML LDMNCs (2 independent patient samples) were plated in duplicate in methylcellulose-based progenitor assays in the absence or presence of human GM-CSF 10 ng/mL and increasing concentrations of the PI3K p110d-specific inhibitor, idelalisib. Data are represented as percentage maximal colony formation, calculated by dividing the number of colonies in each condition by the average number of colonies in the presence of 10 ng/mL GM-CSF. (F) Myelomonocytic cell line U937 or primary JMML LDMNCs (3 independent samples) were treated with GM-CSF, idelalisib alone, or GM-CSF plus idelalisib, followed by examination of AKT (S473) and ERK activation by immunoblot.
Pik3ca
flox/flox and Pik3cd D910A/D910A animals 17, 18 to genetically inactivate p110a and p110d, respectively. Eight weeks after polyI:polyC treatment (300 mg 3 3 intraperitoneal injections), animals were euthanized for functional and biochemical analyses. This study was approved by the Institutional Animal Care and Use Committee of the Indiana University School of Medicine.
Phenotypic and biochemical analyses
Murine bone marrow low-density mononuclear cells (LDMNCs) were plated into methylcellulose-based colony and [ 3 H]-thymidine incorporation assays in the presence or absence of pharmacologic inhibitors, as described. 15, 19, 20 Cell lysate preparation and immunoblotting also have been described. 15, 19, 20 Phenotypically defined progenitor populations from mouse bone marrow were measured using flow cytometry, as described. 21 Idelalisib (formerly known as GS-1101) 22 and GS-9820 23 were provided by Gilead Sciences, Inc, and PD0325901 was purchased from Selleck. Ficoll-purified LDMNCs from JMML patients (meeting World Health Organization diagnostic criteria) or control (Lonza) were plated into methylcellulose-based assays with increasing concentrations of idelalisib. Samples were obtained with informed consent at the University of California, San Francisco, under a locally approved institutional review board protocol and were used in assays under approval from the institutional review board at the Indiana University School of Medicine. This study was conducted in accordance with the Declaration of Helsinki.
Results and discussion
Shp2
D61Y/1 ;Mx1Cre1 mice 16 were crossed with mice bearing a conditional knockout allele of p110a (Pik3ca flox/flox ). 18 Although p110a protein expression was ablated without compensatory upregulation of p110b or p110d, spleen sizes from Shp2 D61Y/1 ; Pik3ca flox/flox ;Mx1Cre1 mice were not reduced substantially compared with those of Shp2 D61Y/1 ;Pik3ca 1/1 ;Mx1Cre1 mice ( Figure 1A ,C). Genetic disruption of p110a also failed to normalize GOF Shp2-induced GM-CSF hypersensitivity in methylcellulose-based progenitor or 3 H-thymidine incorporation assays ( Figure 1D ,E) and did not reduce basal or GM-CSF-stimulated hyperphosphorylation of Erk or Akt ( Figure 1F , compare lanes 7 and 8 with lane 6).
Given the lack of effect of p110a loss, we hypothesized that PI3K catalytic subunit p110d might specifically contribute to GOF Shp2-induced GM-CSF hypersensitivity. Indeed, Shp2 D61Y/1 ;Mx1Cre1 mice homozygous for kinase-dead p110d (Pik3cd
demonstrated reduced spleen size ( Figure 1B,C) , normalized hypersensitivity to GM-CSF ( Figure 1D,E) , and reduced Akt hyperactivation ( Figure 1G , compare lanes 7 and 8 with lanes 5 and 6). Although PI3K canonically activates Akt, genetic disruption of p110d kinase activity also reduced GOF Shp2-induced Erk activation ( Figure 1G , compare lanes 7 and 8 with 5 and 6), indicating that p110d inhibition reduces positive crosstalk to the Ras-Erk pathway. Genetic inhibition of p110d also normalized the skewed hematopoietic progenitor distribution (increased megakaryocyte erythroid progenitor, decreased granulocyte macrophage progenitor reported in Shp2 D61Y/1 ;Mx1Cre1 mice, 16 whereas genetic disruption of p110a failed to do so ( Figure 1H,I ). These findings reveal that p110d, a highly expressed hematopoietic class IA PI3K isoform, is fundamental in GOF Shp2-induced myeloproliferative neoplasm.
We next examined proliferation of GOF Shp2-expressing cells in response to the potent p110d-specific inhibitors, GS-9820 and idelalisib, which are currently under investigation in clinical trials for hematological malignancies. 22 Bone marrow LDMNCs from Shp2 D61Y/1 ;Mx1Cre2 and Shp2 D61Y/1 ;Mx1Cre1 mice were treated with increasing concentrations of GS-9820, and GOF Shp2-expressing cells demonstrated a dose-dependent reduction in proliferation, whereas the wild-type (WT) Shp2-expressing cells were less sensitive ( Figure 2A ). As expected, GS-9820 decreased Akt phosphorylation and, importantly, also reduced Erk phosphorylation ( Figure 2B ), similar to the effects of genetic inhibition of p110d ( Figure 1G ).
Abundant data indicate that MEK inhibition ameliorates GOF Kras-induced and LOF Nf1-induced disease. 7, 8 As both genetic and pharmacologic p110d-specific inhibition reduces Ras-Erk signaling, we evaluated whether p110d cooperates with the Ras-Erk pathway by examining whether inhibition of p110d adds to or is redundant with MEK inhibition. Treatment with PD0325901 reduced proliferation of GOF Shp2-expressing cells, and addition of the p110d-specific inhibitor, GS-9820, further reduced proliferation in a dose-dependent manner ( Figure 2C ). Addition of higher PD0325901 concentrations (0.1 and 0.5 mM) to 1 mM GS-9820 did not further reduce proliferation, indicating that relatively low doses of a MEK inhibitor, in combination with a p110d inhibitor, achieve optimal reduction in proliferation. This is significant, as MEK inhibitors have significant toxicity. 9, 11, 12 Biochemically, although GS-9820 reduced Akt phosphorylation and PD0325901 reduced Erk phosphorylation, PD0325901 induced a compensatory increase in Akt activation in cells expressing GOF Shp2 ( Figure 2D , compare lane 12 with lane 9, observed in multiple experiments). Notably, this upregulation of Akt phosphorylation was not observed in WT Shp2-expressing cells ( Figure 2D , compare lane 5 with lane 2). Addition of GS-9820 to PD0325901 reduced Akt phosphorylation levels to that observed with GS-9820 treatment alone (compare lane 14 with lane 11). These findings suggest that MEK inhibition reduces proliferation by inhibiting Erk activation, and p110d inhibition further reduces proliferation because of effective inhibition of residual (and potentially upregulated) Akt activation in GOF Shp2-expressing cells. Furthermore, the differential effect of MEK inhibition on Akt activation in the GOF Shp2 vs WT Shp2-expressing cells could provide a therapeutic window permitting selective inhibition of disease vs normal cells.
Finally, we examined the effect of idelalisib 22 on primary JMML cell-derived colony growth. Although a single JMML sample failed to demonstrate a response (up to 5 mM idelalisib, data not shown), 2 independent samples demonstrated a dose-dependent reduction in colony formation, whereas control bone marrow cells demonstrated only a modest response ( Figure 2E ). Activation of AKT and ERK was also reduced by idelalisib in the myelomonocytic cell line, U937, and in primary JMML patient samples ( Figure 2F) . Notably, 5 mM is an achievable concentration of idelalisib in humans. 24, 25 Collectively, our findings demonstrate that PI3K catalytic subunit p110d works jointly with the Ras-Erk signaling pathway to promote GOF Shp2-induced hypersensitivity to GM-CSF. These studies support further investigation into the putative selective role of p110d in JMML, as well as into the use of p110d-specific inhibitors, alone or in combination with MEK inhibitors, as a novel therapeutic strategy for JMML.
